Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005069:Evaluation Studies as Topic; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone